Trial Profile
An open-lab, multicenter, prospective study of Icotinib in treating patients with advanced nasopharyngeal carcinoma (NPC)
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 29 Apr 2016
Price :
$35
*
At a glance
- Drugs Icotinib (Primary)
- Indications Nasopharyngeal cancer
- Focus Therapeutic Use
- 29 Apr 2016 New trial record